...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: And we wait.....

Why are we still waiting on the 10 MM share private placement that has been advertised by Zenith since October 2017 as coming soon? What is the timeline for finishing up the ZEN-3694/enzalutamide combo therapy prostate cancer trial? It seems like the results are promising. However, the latest data update at the Zenith AGM showed patients in the 2nd and 3rd cohorts with early cancer progression or adverse event. Hopefully those are just outliers and either the majority of patients are responders, or they can screen better for patients that will respond. Lastly, when will the breast cancer trial start that Zenith has been talking about for so long. Dependent on the 10 MM private placement?

Share
New Message
Please login to post a reply